Table 1.
Recipient, donor, and operative characteristics of 195 liver transplant recipients with hepatocellular carcinoma included in the study.
| Variables | Number (%) or median (IQR) |
|---|---|
| Post-reperfusion AST (U/L) | 850 (486–1625) |
| Post-reperfusion ALT (U/L) | 566 (304–935) |
| Post-reperfusion LDH (U/L) | 2240 (1322–4670) |
| Peak 7-day postoperative bilirubin concentration (mg/dL) | 3.6 (2.1–5.6) |
| Peak 7-day postoperative international normalized ratio | 1.5 (1.3–1.8) |
| Peak 7-day postoperative GGTP activity (U/L) | 663 (396–967) |
| Recipient sex | |
| male | 146 (74.9%) |
| female | 49 (25.1%) |
| Recipient age (years) | 58 (52–61) |
| Hepatitis C virus infection | 132 (67.7%) |
| Hepatitis B virus infection | 89 (45.6%) |
| Model for End-stage Liver Disease | 11 (8–13) |
| Within Milan criteria | 113 (57.9%) |
| Within UCSF criteria | 136 (69.7%) |
| Within Up-to-7 criteria | 144 (73.8%) |
| Number of tumors | 1 (1–3) |
| Diameter of the largest tumor (mm) | 30 (20–45) |
| Total tumor volume (cm3) | 22 (5–62) |
| Alpha-fetoprotein concentration (ng/ml) | 13.8 (5.7–112.8) |
| Microvascular invasion | 52 (26.7%) |
| Poor tumor differentiation | 19 (9.7%) |
| Neoadjuvant treatment | 102 (52.3%) |
| Total ischemic time (hours) | 9.0 (8.0–10.3) |
| Cold ischemic time (hours) | 8.0 (6.9–9.5) |
| Warm ischemic time (minutes) | 55 (44–68) |
| Intraoperative PRBC transfusions (units) | 3 (1–6) |
| Intraoperative FFP transfusions (units) | 6 (4–9) |
| Donor age | 51 (41–60) |
| Donor sex | |
| male | 120 (61.5%) |
| female | 75 (38.5%) |
IQR – interquartile range; AST – aspartate transaminase; ALT – alanine transaminase; LDH – lactate dehydrogenase; UCSF – University of California, San Francisco; PRBC – packed red blood cells; FFP – fresh frozen plasma.